ARS Pharmaceuticals Revenue Accelerates but the Burn Rate Keeps Getting Worse

ARS Pharmaceuticals (NASDAQ: SPRY) reports Q1 2026 earnings before the market opens on Thursday, May 15, 2026, with analysts expecting a loss of $0.53 per share. The central question for investors is whether the company can demonstrate sustained commercial momentum for Neffy, its novel intranasal epinephrine spray, following a sequential revenue decline in Q4 2025 that raised concerns about adoption rates and the company's path to profitability.

Part 1: Earnings Preview

ARS Pharmaceuticals develops and commercializes Neffy, a novel intranasal epinephrine spray approved by the FDA in August 2024 for patients at risk of severe allergic reactions. The company recorded $72.2 million in U.S. net product revenue in Neffy's first full year of commercial sales in 2025, establishing a foothold in the emergency allergy treatment market.

For Q1 2026, analysts expect ARS Pharmaceuticals to report a loss of $0.53 per share on revenue of approximately $22.25 million. The company most recently reported Q4 2025 results on March 9, 2026, posting a loss of $0.42 per share. Compared to the same quarter last year (Q1 2025), when the company lost $0.35 per share, the consensus estimate represents a 51.43% increase in losses year-over-year, reflecting continued heavy investment in commercial expansion despite growing revenue.

Three key themes define this earnings story:

Commercial Momentum and Prescription Growth: Investors will scrutinize whether Neffy prescriptions are accelerating after the sequential revenue decline from $31.3 million in Q3 2025 to $28.1 million in Q4 2025. The company's expansion of its sales force from 106 to 150 representatives starting in Q2 2026 signals confidence, but investors need evidence that prescribing depth among allergists is increasing and that the "Get Neffy on Us" program is driving patient adoption.

Payer Access and Prior Authorization Barriers: With approximately 93% commercial coverage achieved by the end of 2025, the focus shifts to execution—specifically, whether ARS can reduce prior authorization friction and secure unrestricted access with major payers. Any progress on this front would be a significant catalyst for prescription growth.

International Expansion Timeline: Regulatory approval in Canada is expected in Q2 2026, with a commercial launch later in the year through the company's partnership with ALK. Investors will look for concrete timelines and commentary on partner-led launches in Europe, China, Japan, and Australia, which represent critical diversification opportunities for the revenue base.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. The consensus rating stands at Hold with an average price target of $24.25, suggesting significant upside potential if the company can demonstrate sustained commercial traction. However, the lack of 2026 revenue guidance and the full-year 2025 net loss of $171.3 million have kept investors on the sidelines, waiting for clearer evidence of a path to profitability.

Part 2: Historical Earnings Performance

ARS Pharmaceuticals has delivered a mixed earnings track record over the past four quarters, with two in-line results and two misses. In Q1 2025, the company reported a loss of $0.35 per share, matching the consensus estimate exactly. The following quarter (Q2 2025) saw a 12.20% miss, with a reported loss of $0.46 per share against an estimate of $0.41. Q3 2025 brought another disappointment, with a 15.56% miss as the company lost $0.52 per share versus expectations of $0.45. Most recently, Q4 2025 results came in line with estimates at a loss of $0.42 per share.

The pattern reveals a company in the early stages of commercialization, where losses have widened as revenue ramps but operating expenses grow even faster. The two consecutive misses in Q2 and Q3 2025 suggest the company faced challenges in managing the pace of investment relative to revenue growth during the critical launch phase of Neffy. The return to in-line results in Q4 2025 may indicate improved cost discipline, but with losses still expected to deepen year-over-year in Q1 2026, investors remain focused on when the company can demonstrate a credible path toward narrowing losses as revenue scales.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

ARS Pharmaceuticals typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, and Day +1 captures follow-through momentum.

Historical price action around earnings reveals significant volatility, with an average absolute Day 0 move of 8.26% and Day +1 move of 4.10%. The most dramatic reaction came in March 2025, when the stock surged 22.83% on Day 0 before giving back 13.63% the following session—a pattern suggesting initial enthusiasm followed by profit-taking. More recently, the November 2024 report triggered a sharp 15.23% decline on Day 0, while the March 2026 report produced minimal movement with just a 0.11% decline on Day 0 and a 2.10% drop on Day +1.

The data shows intraday trading ranges are consistently wide, averaging 14.49% on Day 0 and 9.17% on Day +1, reflecting the stock's high volatility and the market's uncertainty about the company's commercial trajectory. Investors should prepare for substantial price swings in either direction, particularly given the stock's tendency to see follow-through moves on Day +1 that can either amplify or reverse the initial reaction.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 13.60% for this earnings release, which is notably higher than the stock's average historical Day 0 move of 8.26% but below the average intraday range of 14.49%. This suggests options traders are anticipating above-average volatility, likely reflecting heightened uncertainty around commercial execution and the sustainability of Neffy's revenue growth trajectory.

Part 3: What Analysts Are Saying

Analyst sentiment toward ARS Pharmaceuticals reflects cautious optimism with a consensus rating of 4.67 out of 5.00, indicating a Buy recommendation. The current breakdown shows 5 Strong Buy ratings, 0 Moderate Buy ratings, 1 Hold rating, and 0 Sell ratings among the 6 analysts covering the stock. The average price target stands at $24.25, with a high estimate of $34.00 and a low estimate of $12.00.

Sentiment has deteriorated over the past month, with the number of Strong Buy ratings declining from 7 to 5, while the average recommendation slipped from 4.75 to 4.67. This modest downgrade reflects growing caution among analysts following the sequential revenue decline in Q4 2025 and the company's decision not to provide 2026 revenue guidance.

Despite the recent pullback in enthusiasm, the consensus price target of $24.25 implies substantial upside of approximately 205% from the current price of $7.94. This wide gap between the current price and analyst targets suggests the market is pricing in significant execution risk, while analysts maintain conviction that successful commercial expansion of Neffy could drive meaningful appreciation. The broad range of price targets—from $12.00 to $34.00—underscores the uncertainty around the company's ability to translate its FDA-approved product into sustained revenue growth and eventual profitability.

Part 4: Technical Picture

ARS Pharmaceuticals enters earnings with a deteriorating technical picture. The Barchart Technical Opinion currently shows a Sell signal at 80%, strengthening from 56% Sell last week and 100% Sell last month. This intensifying bearish signal reflects mounting downward pressure as the stock has failed to gain traction ahead of the earnings release.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, though not at extreme levels
• Medium-term (100% Sell): Strong sell signal suggests clear weakness in the intermediate timeframe with no signs of stabilization
• Long-term (100% Sell): Strong sell signal reflects persistent weakness in the longer-term trend, indicating sustained downward pressure

Trend Characteristics: The combination of Average strength and Average direction suggests the stock is experiencing a typical downtrend without extreme momentum in either direction, creating a cautious environment heading into earnings.

The stock is trading at $7.94, positioned below all major moving averages: the 5-day ($8.38), 10-day ($8.66), 20-day ($8.39), 50-day ($8.33), 100-day ($9.33), and 200-day ($10.16). This complete breakdown below key technical levels indicates persistent selling pressure and a lack of support. The 50-day moving average at $8.33 represents the nearest resistance level, while the stock's position near its 52-week low of $6.66 suggests limited downside cushion. The overall technical setup is cautionary heading into earnings, with the stock showing no signs of stabilization and all timeframes pointing to continued weakness. Investors should be prepared for heightened volatility, as any disappointment could push the stock toward new lows, while a strong beat might trigger a sharp short-covering rally given the deeply oversold conditions.